RWD80 Use of Ml Model to Predict Biologic to Biosimilar Switch in Inflammatory Bowel Disease

Abstract

To identify the predictors of switching from biologic to Infliximab biosimilar in Inflammatory Bowel Disease (IBD) patients. According to CDC, patients with IBD tend to have higher healthcare utilization including doctor’s visits, ER visits, and GI-related surgeries as compared to non-IBD patients. The recent treatment modalities in the form of biologics and biosimilars have proven beneficial in halting disease progression and improving quality of life. Biosimilars hold value in terms of providing cost-effective treatment still there is low penetration observed for biosimilar usage.